Primary cutaneous lymphomas differ significantly from their nodal equivalents in clinical behaviour and prognosis, and often require a different therapeutic approach. Since currently used classification systems for non-Hodgkin lymphomas do not or insufficiently recognize the special character of these lymphomas, primary cutaneous lymphomas are not uncommonly diagnosed incorrectly, and/or treated inappropriately with unnecessarily aggressive therapies. For that reason the Cutaneous Lymphoma Group of the European Organization for Research and Treament of Cancer (EORTC) has recently proposed a separate classification for the group of primary cutaneous lymphomas. The EORTC Classification is consistently based on a combination of clinical, histological, immunophenotypical and genetic criteria, and includes well-defined and recognizable disease entities. It contains a limited number of cutaneous T-cell lymphomas and cutaneous B-cell lymphomas, which comprise more than 95% of all primary cutaneous lymphomas. The clinical significance of this classification has been validated by long-term follow-up data of more than 800 patients with a primary cutaneous lymphoma.
Introduction
The term 'primary cutaneous lymphoma' designates a heterogeneous group of cutaneous T-cell lymphomas (CTCL) and cutaneous B-cell lymphomas (CBCL), which present in the skin with no evidence of extracutaneous disease at the time of diagnosis. They are after the group of gastrointestinal lymphomas the second most common group of extranodal non-Hodgkin lymphomas with an estimated annual incidence of 1-1.5/ 100,000. In the last decade major differences between primary cutaneous lymphomas and morphologically similar primary nodal lymphomas with or without secondary cutaneous involvement have been demonstrated [1] . Primary cutaneous lymphomas often have a completely different clinical behaviour and prognosis, and consequently, require a different therapeutic approach. In addition, differences in the presence of specific translocations (e.g., t(2;5) in anaplastic large-cell lymphomas), the expression of corresponding oncogenes (e.g., ALK), the presence of viral sequences or antigens (e.g., EBV), and the expression of adhesion receptors involved in tissue-related lymphocyte homing (e.g., cutaneous lymphocyte antigen, CLA) have been demonstrated. Perhaps the most fundamental difference between primary cutaneous lymphomas and malignant lymphomas at other sites (as well), is that primary cutaneous lymphomas can be seen, and that therefore the clinical behaviour, including both tumor progression and regression, can be monitored very closely. Moreover, the accessibility of primary cutaneous lymphomas allows an optimal correlation between clinical appearance and behaviour on the one hand, and histological, phenotypical and genetic aspects on the other.
Until recently, classifications for non-Hodgkin lymphomas did not make distinction between nodal and extranodal lymphomas, and thus neither between primary and secondary cutaneous lymphomas. Since these classifications did not communicate to the clinician that these primary cutaneous lymphomas have a different clinical behaviour, and consequently require a different therapeutic approach, primary cutaneous lymphomas were and still are not uncommonly treated as nodal lymphomas with unnecessarily aggressive therapies. A second disadvantage of existing classification schemes was that they were only or largely based on histologic criteria. Even the recent classifications (Revised European-American for Lymphoid Neoplasms (R.E.A.L.) Classification [2] , proposed WHO Classification [3] ), which aim to include only disease entities, still contain large histologically defined subgroups (e.g., diffuse large B-cell lymphoma; peripheral T-cell lymphoma, unspecified). It should be realized that for haemato-oncologists the histologic diagnosis, c.q. classification, is the final diagnosis (working diagnosis), which determines to a great extent further management and treatment. How- 
EORTC Classification: Basic principles
The EORTC Classification is not just a new classification, but compared to the existing classification schemes a novel approach in the diagnosis and classification of primary cutaneous lymphomas. It is the only classification, which is consistently based on a combination of histological, immunophenotypical, molecular as well as clinical criteria, and thus only includes disease entities. It contains a limited number of well-defined types of CTCL and CBCL, which together comprise more than 95% of all primary cutaneous lymphomas. [1, 4] . For clinicians the EORTC Classification has the major advantage that it contains only well-defined and recognizable disease entities, and that it provides detailed information regarding their management, treatment and prognosis. For pathogists, usage of a classification, which is not only based on histological, immunophemotypical and molecular criteria, but also on clinical criteria, is more difficult. In many instances their histologic diagnosis is not the final diagnosis, but in fact a differential diagnosis. Discussion between pathologist and clinician, who should provide relevant clinical information, is essential to make a definite diagnosis [5] .
EORTC Classification: Current controversies
The publication of this new classification has resulted not only in discussions on the definition and terminology of some types of CTCL and CBCL, but also in a discussion whether or not organ-based classification schemes, separate from existing haematopathologic classification schemes for non-Hodgkin lymphomas, should be used [6] [7] [8] . Indeed, one may wonder if a separate classification for the group of primary cutaneous lymphomas is still required, since recent proposals (R.E.A.L. Classification, proposed WHO Classification) also aim to include disease entities rather than histologic subgroups, and tend to incorporate an increasing number of well-defined types of extranodal lymphomas, including primary cutaneous lymphomas. The pros and cons of the R.E.A.L. Classification and the proposed WHO Classification, as compared to the EORTC Classification, will be discussed below.
EORTC versus R.E.A.L. Classification
Whereas previous classifications for non-Hodgkin lymphomas (Working Formulation, updated Kiel classification) were based on histologic criteria, the basic concept of the R.E.A.L. Classification [2] is that malignant lymphomas should be viewed as a group of disease entities, defined by a constellation of morphological, immunological, genetic and clinical criteria. In addition it is recognized that the site of presentation is important, and that extranodal lymphomas are not identical to their nodal counterparts. Although the authors suggest that the R.E.A.L. Classification is simply a list of 'real' disease entities, several of these 'real entities', e.g., the group of diffuse large B-cell lymphomas and the group of peripheral T-cell lymphomas, unspecified, are in fact broad histologic subgroups. Unortunately, approximately 20% of primary cutaneous lymphomas, including most CBCL and most CTCL other than mycosis fungoides (MF), Sezary's syndrome (SS) and the group of CD30-positive lymphoproliferations, belong to one of these two groups.
Recent reports suggest that the R.E.A.L. Classification can be applied very well on cutaneous lymphomas, and should therefore be used also by dermatologists [6] . However, the question whether usage of the R.E.A.L. Classification also provides useful clinical information, and results in appropriate management and treatment, is not addressed. In fact, studies validating the clinical usefullness of the R.E.A.L. Classification for the group of primary cutaneous lymphomas have never been performed. Therefore, it seems that the primary goal of the R.E.A.L. Classification, which was proposed by a group of haematopathologists, is a correct and reproducible (histologic) diagnosis. In contrast, the basic philosophy of the EORTC Classification, which was based on detailed clinicopathologic studies performed by collaborative groups of dermatologists and pathologists, has always been that a classification should be above all clinically relevant, and that the terms used in such a classification should provide the clinician all information necessary for adequate management and treatment.
In conclusion, the rationale for using the R.E.A.L. Classification for the group of primary cutaneous lymphomas is above all that pathologists and clinicians use the same classification, c.q. terminology, facilitating an optimal communication between both groups. However, the diagnostic accuracy and clinical relavance of the R.E.A.L. Classification for the group of primary cutaneous lymphomas is uncertain.
EORTC versus proposed WHO Classification
The proposed WHO classification [3] is similar to the R.E.A.L. Classification, although some modifications have been made. With respect to the group of primary cutaneous lymphomas, it is fortunate to note that in the proposed WHO Classification MF, MF variants, SS and the full spectrum of primary cutaneous CD30-positive lymphoproliferative disorders are defined more precisely, and now closely match the definitions of the EORTC classification (Table 2) . Together, these entities comprise almost 90% of the CTCL, and more than 70% of all primary cutaneous lymphomas. Remaining controversies regarding the groups of CTCL and CBCL have been reviewed recently [8] , and are summarized below (see Table 2 ).
Cutaneous T-cell lymphomas
A minor discrepancy between the EORTC Classification and the proposed WHO Classification concerns the terminology of primary cutaneous CD30-positive lymphomas lacking the typical anaplastic morphology. Based on studies demonstrating that anaplastic and non-anaplastic primary cutaneous CD30-positive large T-cell lymphomas have the same clinical presentation, clinical behaviour and excellent prognosis [1, 9] , in the EORTC Classification both groups are included in the group primary cutaneous CD30-positive large T-cell lymphomas, and further distinction is not made. In the R.E.A.L. and the WHO Classifications these CD30-positive nonanaplastic large-cell lymphomas may be considered as histologic variants of anaplastic large-cell lymphomas, or perhaps be classified as peripheral T-cell lymphoma, unspecified. Studies comparing the clinical characteristics and outcome between these non-cutaneous CD30-positive anaplastic and non-anaplastic large-cell lymphomas should be performed to solve this problem.
Moreover, in the group of peripheral T-cell lymphoma, unspecified no distinction between small and large T-cell lymphomas is made. In contrast, based on studies demonstrating that primary cutaneous CD30-negative T-cell lymphomas with a predominance of small or medium-sized pleomorphic T cells have a much better prognosis than primary cutaneous CD30-negative large pleomorphic or immunoblastic T-cell lymphomas [4, 10] , in the EORTC Classification distinction is made between primary cutaneous CD30-negative large T-cell lymphomas and a provisional group of primary cutaneous CD30-negative small/medium-sized pleomorphic T-cell lymphomas [1] .
Finally, rare cases of primary cutaneous angiocentric lymphoma or NK/T-cell lymphoma are not (yet) recognized as a separate group in the EORTC Classification. Since their clinical behaviour did not differ significantly from other CD30-negative CTCL, these lymphomas have been included, dependent on the predominant tumor cell size, in the group of primary cutaneous CD30-negative large T-cell lymphomas or in the group of primary cutaneous CD30-negative small/medium-sized pleomorphic T-cell lymphomas [11] . Additional studies on larger groups of primary cutaneous NK/T-cell lymphomas are necessary to decide, whether or not these lymphomas should be considered separately.
Cutaneous B-cell lymphomas
In contrast to the group of CTCL, there is still considerable confusion and disagreement regarding the terminology and classification of the group of CBCL [12, 13] . The main controversies concern the terminology of the group of primary cutaneous follicle center cell lymphomas (PCFCCL) and the group of primary cutaneous large B-cell lymphoma (PCLBCL) of the leg.
The term PCFCCL was introduced in 1987 as an encompassing term for cutaneous lymphomas, that were composed of centroblasts and (large) centrocytes and were classified as either centroblastic/centrocytic or centroblastic according to the updated Kiel classification. Clinically, most patients present with localized skin lesions on the head or trunk, rarely disseminate to extracutaneous sites (ca. 5%) and have an excellent prognosis, irrespective of the histologic appearance (five-year survival >95%) [14] . The term PCFCCL has become confusing, when the REAL classification introduced the term follicle center lymphoma, -renamed follicular lymphoma in the WHO Classification -for nodal B-cell lymphomas with a follicular growth pattern, and it appeared that PCFCCL do not express BCL-2 protein and are not associated with the t(14;18) translocation. However, an alternative term for this distinct type of CBCL is not readily available. In the R.E.A.L. and the proposed WHO Classification, this well-defined disease entity would be subdivided into three different histologic subgroups (see Table 1 ), which conflicts with the basic principle of these classifications to include only 'real entities'. Moreover, the majority of these PCFCCL would be classified as a diffuse large B-cell lymphoma, which would almost certainly result in overtreatment with muliagent chemotherapy rather than radiotherapy.
Primary cutaneous large B-cell lymphoma of the leg
PCLBCL of the leg clearly differ from large B-cell lymphomas arising at other sites, mainly on the head and the trunk, which are included in the group of PCFCCL. PCLBCL of the leg particularly affect elderly people, and show a higher relapse rate and a more unfavorable prognosis [4, 15] , particularly in patients presenting with skin lesions at both lower legs [16] . The differences between these PCLBCL of the leg and large B-cell lymphomas contained within the group of PCFCCL are summarized in Table 2 . It is expected that the European multicenter study currently being conducted on 180 primary cutaneous large B-cell lymphomas will reveal to what extent differences in age, site, tumor cell morphology and BCL-2 expression contribute to the different clinical behaviour between these two groups.
Conclusions
By delineating well-defined and recognizable disease entities, the EORTC Classification is at present the best guide to optimal treatment and management of these primary cutaneous lymphomas. It is, however, fortunate to note that there is growing consensus, that classifica-tion systems for non-Hodgkin lymphomas should also take into consideration clinical aspects, including the site of presentation, as illustrated by the increasing number of well-defined types of extracutaneous lymphomas in the R.E.A.L. and the proposed WHO Classification. These common principles form a solid basis, which should ultimately result in one classification system, which is reproducible, easy-to-use, and above all clinically relevant, also for the group of primary cutaneous lymphomas.
